Form 4 for NVCT Nuvectis Pharma, Inc.
Accepted 2023-03-28 00:00:00 ET · period of report 2023-03-27 · accession 0001104659-23-037421 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-28 | 2023-03-27 | NVCT | Poradosu Enrique | Chief Science, Business Off | P - Purchase | $11.55 | +500 | 1.37M | +0.0% | +$5,775 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-27 | P | A | 500 | $11.55 | 1,373,819 | D | — | — | (F1) Includes 48,399 shares of restricted stock and 175,000 restricted stock units. |